동국생명과학

303810KOSDAQ의약품 제조업

56.0 / 100

Reference Date: 2026-04-13

Financial Score24.5 / 40

News Sentiment12.5 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly down 4.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Dongkook Life Science is a specialized contrast agent manufacturer focusing on X-ray, CT, and MRI imaging diagnostics, with iodinated and gadolinium-based contrast agents as core products. Driven by aging populations and rising diagnostic demand, the company has expanded its market share to 22.6% in 2024. It is diversifying its portfolio through medical equipment distribution and AI medical device expansion.

Number of Employees

203people

Average Salary

64.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.00Industry Average 14.805.0Point

In line with industry avg

PBR

0.80Industry Average 1.044.0Point

In line with industry avg

ROE

7.32Industry Average 4.425.5Point

1.7x industry avg (good)

Debt Ratio

4.26Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2024~20253.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼1.1% (1-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲9.5% (1-year basis)

ROE Trend

1.0 / 4

Avg ROE 5.0% (improving, 2yr)

Detailed News Sentiment

4 totalPositive 1Neutral 1Negative 0Average Sentiment Score 50

Neutral
인벤테라, 질환 특화 조영제로 시장 선점…4월 상장 추진
인벤테라는 질환 특화 조영제로 시장을 선점하고 4월 코스닥 상장을 추진하며, 동국생명과학과의 협력을 통해 제품 수출 및 기술 이전을 모색하고 있습니다.
Positive
인벤테라 대표 "MRI 조영제 넘어 글로벌 나노의약품 개발사 도약"
인벤테라는 동국생명과학과 협력하여 세계 최초 철 기반 MRI 조영제 상업화를 추진하며, 나노의약품 개발 전문기업으로 도약할 청사진을 공개했습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 3,300Won52-week high 5,15052-week low 3,210

1-month return2.0Point

1m -4.35% (slight drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-09
Neutral기업설명회(IR)개최2026-04-07
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-23
Neutral정기주주총회결과2026-03-20